(Q37519312)

20 August 2017

1 reference

title

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? (English)

1 reference

20 August 2017

0 references

1 reference

1 reference

4

John R Mascola

1 reference

20 August 2017

2

Lynn Morris

1 reference

20 August 2017

3

Dennis R Burton

1 reference

20 August 2017

Leonidas Stamatatos

1

1 reference

PubMed ID

19525964

20 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

20 August 2017

1 reference

20 August 2017

15

1 reference

20 August 2017

8

1 reference

20 August 2017

866-870

1 reference

https://scigraph.springernature.com/pub.10.1038/nm.1949

20 August 2017

0 references

cites work

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

1 reference

12 December 2020

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

1 reference

12 December 2020

Antibody neutralization and escape by HIV-1

1 reference

12 December 2020

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth

1 reference

12 December 2020

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

12 December 2020

Vaccines: correlates of vaccine-induced immunity

1 reference

12 December 2020

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

1 reference

12 December 2020

Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.

1 reference

12 December 2020

Progress and obstacles in the development of an AIDS vaccine

1 reference

12 December 2020

HIV vaccine design and the neutralizing antibody problem

1 reference

12 December 2020

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

12 December 2020

Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies

1 reference

12 December 2020

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

1 reference

12 December 2020

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

12 December 2020

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

1 reference

12 December 2020

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

12 December 2020

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

12 December 2020

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

1 reference

12 December 2020

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

1 reference

12 December 2020

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

1 reference

12 December 2020

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

12 December 2020

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

1 reference

12 December 2020

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

1 reference

12 December 2020

Challenges in the development of an HIV-1 vaccine

1 reference

12 December 2020

Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent i

1 reference

12 December 2020

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa

1 reference

12 December 2020

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

1 reference

12 December 2020

Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.

1 reference

12 December 2020

Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization

1 reference

12 December 2020

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

12 December 2020

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

1 reference

12 December 2020

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection

1 reference

12 December 2020

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

12 December 2020

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

1 reference

12 December 2020

Protective immunity following vaccination: how is it defined?

1 reference

12 December 2020

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro

1 reference

12 December 2020

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

12 December 2020

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

12 December 2020

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

12 December 2020

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

1 reference

12 December 2020

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

1 reference

12 December 2020

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals

1 reference

12 December 2020

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

1 reference

12 December 2020

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning

1 reference

12 December 2020

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

1 reference

12 December 2020

Identifiers

DOI

10.1038/NM.1949

1 reference

20 August 2017

1 reference

PubMed ID

19525964